John Thievon named president of Dey Pharma

Mylan has named John Thievon as president of its integrated speciality pharmaceutical business Dey Pharma.

Thievon joins from MiddleBrook Pharmaceuticals where he was president and CEO.

He has more than 20 years experience in the healthcare industry and while serving as Middlebrook's CEO he oversaw the US pharma company's expansion from 18 employees to 450 and subsequent takeover by Victory Pharma.

He also worked as executive vice president of commercial operations for Adams Respiratory Therapeutics and spent four years at IMS Health.

Mylan's president Heather Bresch said: “Dey has been, and continues to be, a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.